ARWR
Price
$79.03
Change
-$0.24 (-0.30%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
11.13B
40 days until earnings call
Intraday BUY SELL Signals
LSTA
Price
$3.37
Change
-$0.01 (-0.30%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
30.69M
52 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARWR vs LSTA

ARWR vs LSTA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARWR vs. LSTA commentary
Jun 27, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and LSTA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2026
Stock price -- (ARWR: $79.03 vs. LSTA: $3.38)
Brand notoriety: ARWR: Notable vs. LSTA: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 896% vs. LSTA: 17%
Market capitalization -- ARWR: $11.13B vs. LSTA: $30.78M
ARWR [@Biotechnology] is valued at $11.13B. LSTA’s [@Biotechnology] market capitalization is $30.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $124.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 0 FA rating(s) are green whileLSTA’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 0 green, 5 red.
  • LSTA’s FA Score: 0 green, 5 red.
According to our system of comparison, both ARWR and LSTA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 5 TA indicator(s) are bullish while LSTA’s TA Score has 5 bullish TA indicator(s).

  • ARWR’s TA Score: 5 bullish, 3 bearish.
  • LSTA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than LSTA.

Price Growth

ARWR (@Biotechnology) experienced а -3.41% price change this week, while LSTA (@Biotechnology) price change was -3.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.08%. For the same industry, the average monthly price growth was +1.67%, and the average quarterly price growth was +1916.03%.

Reported Earning Dates

ARWR is expected to report earnings on Aug 06, 2026.

LSTA is expected to report earnings on Aug 17, 2026.

Industries' Descriptions

@Biotechnology (+4.08% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($11.1B) has a higher market cap than LSTA($30.7M). LSTA YTD gains are higher at: 81.720 vs. ARWR (19.039). LSTA has higher annual earnings (EBITDA): -17.2M vs. ARWR (-134.47M). ARWR has more cash in the bank: 1.78B vs. LSTA (13.1M). LSTA has less debt than ARWR: LSTA (0) vs ARWR (989M). ARWR has higher revenues than LSTA: ARWR (622M) vs LSTA (170K).
ARWRLSTAARWR / LSTA
Capitalization11.1B30.7M36,156%
EBITDA-134.47M-17.2M782%
Gain YTD19.03981.72023%
P/E Ratio48.72N/A-
Revenue622M170K365,882%
Total Cash1.78B13.1M13,618%
Total Debt989M0-
FUNDAMENTALS RATINGS
ARWR vs LSTA: Fundamental Ratings
ARWR
LSTA
OUTLOOK RATING
1..100
1819
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
47
Fair valued
PROFIT vs RISK RATING
1..100
94100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
3544
P/E GROWTH RATING
1..100
34100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LSTA's Valuation (47) in the null industry is somewhat better than the same rating for ARWR (91) in the Biotechnology industry. This means that LSTA’s stock grew somewhat faster than ARWR’s over the last 12 months.

ARWR's Profit vs Risk Rating (94) in the Biotechnology industry is in the same range as LSTA (100) in the null industry. This means that ARWR’s stock grew similarly to LSTA’s over the last 12 months.

ARWR's SMR Rating (99) in the Biotechnology industry is in the same range as LSTA (99) in the null industry. This means that ARWR’s stock grew similarly to LSTA’s over the last 12 months.

ARWR's Price Growth Rating (35) in the Biotechnology industry is in the same range as LSTA (44) in the null industry. This means that ARWR’s stock grew similarly to LSTA’s over the last 12 months.

ARWR's P/E Growth Rating (34) in the Biotechnology industry is significantly better than the same rating for LSTA (100) in the null industry. This means that ARWR’s stock grew significantly faster than LSTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRLSTA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 10 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signal:
Gain/Loss:
LSTA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CAG13.780.17
+1.25%
Conagra Brands
VZ46.070.39
+0.85%
Verizon Communications
DVLT0.34N/A
-1.09%
Datavault AI Inc.
FUSE1.03-0.02
-1.90%
Fusemachines Inc.
WEN7.32-0.54
-6.87%
Wendy's Company

LSTA and

Correlation & Price change

A.I.dvisor tells us that LSTA and RAIN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LSTA and RAIN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSTA
1D Price
Change %
LSTA100%
-1.74%
RAIN - LSTA
29%
Poorly correlated
-0.05%
MLEC - LSTA
27%
Poorly correlated
+0.84%
ASND - LSTA
26%
Poorly correlated
+9.82%
VIR - LSTA
25%
Poorly correlated
-0.75%
SLDB - LSTA
25%
Poorly correlated
-4.22%
More